bromocriptine (parlodel) Report issue

Small molecule Approved FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bromocriptine is an ergot derivative with potent dopamine receptor agonist activity, which activates post-synaptic dopamine receptors. Bromocriptine is indicated for the treatment of dysfunctions associated with hyperprolactinemia. Bromocriptine therapy is indicated in the treatment of acromegaly and in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson’s disease. It is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Some commonly reported adverse reactions include nausea, fatigue, dizziness, vomiting and headache. Bromocriptine may interact with dopamine antagonists, butyrophenones and certain other agents.   NCATS

Chemistry

  • SMILES: CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C=C4c5cccc6[nH]c(Br)c(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12
  • InChIKey: OZVBMTJYIDMWIL-AYFBDAFISA-N
  • Mol. Mass: 654.61
  • ALogP: 3.19
  • ChEMBL Molecules:
    bromocriptine  
    bromocriptine mesylate  
    bromocryptine  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.2809

United States

$0.3388 - $6.8790
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

2-bromo-alpha-ergocryptine | 2-bromo-alpha-ergokryptin | 2-bromo-alpha-ergokryptine | 2-bromoergocriptine | 2-bromo-α-ergocryptine | 2-bromo-α-ergokryptin | 2-bromo-α-ergokryptine | (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)-3',6',18-trioxoergotaman | (5'alpha)-2-bromo-12'-hydroxy-2'-(1-methylethyl)-5'-(2-methylpropyl)ergotaman-3',6',18-trione | (5'alpha)-2-bromo-12'-hydroxy-5'-isobutyl-2'-isopropyl-3',6',18-trioxoergotaman | bromocriptin | bromocriptina | bromocriptine | bromocriptine mesilate | bromocriptine mesylate | bromocriptinum | bromocryptine | bromoergocriptine | bromoergocryptine | cb-154 | cb-154 mesylate | cycloset | ergolactin | parlodel

Organizations (83)

Research & Development (76)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (41)

Approved Indications (8)


 

Acromegaly

Adenoma

Diabetes Mellitus, Type 2

Hyperprolactinemia

Hypogonadism

Infertility

Infertility, Female

Parkinson Disease

Experimental Indications - Clinical Trial Phases 1-4 (36)


 

Adenomyosis (Phase 1)

Alzheimer Disease (Phase 1/Phase 2)

Anorexia Nervosa (Early Phase 1)

Atrial Fibrillation (Phase 4)

Brain Injuries (Phase 1/Phase 2)

Brain Injuries, Traumatic (Phase 1/Phase 2)

Cardiomyopathies (Phase 4)

Cerebral Hemorrhage (Phase 1/Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 ()

Diabetic Neuropathies (Phase 4)

Feeding Behavior (Phase 3)

Fever (Phase 1/Phase 2)

Glucose Intolerance (Phase 4)

Healthy Volunteers (Phase 2/Phase 3)

Hematoma, Subdural (Phase 1/Phase 2)

Hyperaldosteronism (Phase 4)

Hyperprolactinemia (Phase 3)

Hypertension (Phase 4)

Insulin Resistance (Phase 3)

Intellectual Disability (Phase 2)

Ischemia (Phase 4)

Ischemic Stroke (Phase 1/Phase 2)

Macular Edema (Phase 1/Phase 2)

Mutation (Phase 1/Phase 2)

Obesity (Phase 3)

Ovarian Hyperstimulation Syndrome (Phase 2)

Parkinson Disease ()

Pituitary Neoplasms (Phase 4)

Polycystic Ovary Syndrome (Phase 3)

Prolactinoma (Phase 4)

Schizophrenia (Phase 4)

Scleroderma, Diffuse (Phase 3)

Stereotyped Behavior (Phase 2)

Subarachnoid Hemorrhage (Phase 1/Phase 2)

Tachycardia, Ventricular (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 49
  • # of Trial Organizations: 76

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue